Front Row Advisors’s Novavax NVAX Stock Holding History

Front Row Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-200	Closed	-$1K	–	927
2023 Q1	$1K	Hold	200	–	–	﹤0.01%	882
2022 Q4	$2K	Hold	200	–	–	﹤0.01%	794
2022 Q3	$4K	Hold	200	–	–	﹤0.01%	711
2022 Q2	$10K	Hold	200	–	–	﹤0.01%	518
2022 Q1	$15K	Hold	200	–	–	0.01%	470
2021 Q4	$29K	Hold	200	–	–	0.01%	348
2021 Q3	$41K	Hold	200	–	–	0.02%	290
2021 Q2	$43K	Hold	200	–	–	0.02%	283
2021 Q1	$36K	Hold	200	–	–	0.02%	297
2020 Q4	$22K	Hold	200	–	–	0.01%	369
2020 Q3	$25K	Buy	+200	New	+$24.4K	0.01%	344

Other funds holding NVAX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Front Row Advisors's NVAX Position: Q2 2023 in Review

Front Row Advisors sold out of Novavax (NVAX) in Q2 2023, closing a stake of 200 shares — an estimated $1K sold.

Front Row Advisors first reported a position in NVAX in Q3 2020 and held it in 11 quarters. The position peaked at $43K in Q2 2021. 215 funds tracked by Wall St. Rank hold NVAX as of Q2 2023.

Front Row Advisors reported no remaining Novavax position as of Q2 2023 after selling out during the quarter.
Front Row Advisors sold 200 Novavax shares in Q2 2023, an estimated $1K.
Front Row Advisors first reported a position in Novavax in Q3 2020 and held it in 11 quarters.
Front Row Advisors's Novavax position peaked at $43K in Q2 2021.
215 funds tracked by Wall St. Rank held Novavax as of Q2 2023.

Based on Front Row Advisors's 13F filing for Q2 2023, filed 15 Aug 2023.